Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Longboard Pharmaceuticals, Inc. - Common Stock (NQ: LBPH )

59.98 UNCHANGED
Last Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Longboard Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Crude Oil Down 2%; Tesla Deliveries Top Estimates
U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite falling more than 250 points on Tuesday. The Dow traded up 0.01% to 37,691.77 while the NASDAQ fell 1.78% to... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of... 
Via Benzinga
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
With Longboard Pharmaceuticals delivering positive clinical trial data, LBPH stock soared on the positive therapeutic implications. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Dow Turns Higher; Anavex Life Sciences Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.13% to 37,739.18 while the NASDAQ fell 1.29% to 14,818.23. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for Longboard Pharmaceuticals
Via Benzinga
The Latest Analyst Ratings for Longboard Pharmaceuticals
Via Benzinga
Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Longboard Pharmaceuticals, Inc. 
Via Benzinga
Neurology-Focused Longboard Pharmaceuticals' Stock Soars Over 200% Today - Here's Why
Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental  
Via Benzinga
Dow Down 100 Points; US Manufacturing PMI Falls In December
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.28% to 37,584.41 while the NASDAQ... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Latest Analyst Ratings for Longboard Pharmaceuticals
Via Benzinga
Recap: Longboard Pharmaceuticals Q1 Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Three Upcoming Investor Conferences in November
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Announces Speakers for Investor & Analyst Event in New York on October 11, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on October 11, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Three Upcoming Investor Conferences
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present Data at Upcoming Medical Meetings
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Completes Enrollment of Phase 1b/2a PACIFIC Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Present at Upcoming Investor Conferences
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals to Participate in Fireside Chat with Cantor on Friday, June 30, 2023
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
From Longboard Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 27, 2023
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.